Nothing Special   »   [go: up one dir, main page]

Renert-Yuval et al., 2019 - Google Patents

What's new in atopic dermatitis

Renert-Yuval et al., 2019

Document ID
3012374423167172381
Author
Renert-Yuval Y
Guttman-Yassky E
Publication year
Publication venue
Dermatologic clinics

External Links

Snippet

Atopic dermatitis (AD), perhaps the most common inflammatory skin disease, with an increasing prevalence worldwide, is characterized by chronic symptoms of eczema and pruritus. 1 The quality of life of AD patients is significantly impaired, with higher prevalence …
Continue reading at www.derm.theclinics.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases; Films; Fibres of the matrix type containing drug

Similar Documents

Publication Publication Date Title
Renert-Yuval et al. What’s new in atopic dermatitis
Renert-Yuval et al. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
Furue Regulation of skin barrier function via competition between AHR axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis
Dubin et al. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
Bissonnette et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial
Bieber Interleukin‐13: targeting an underestimated cytokine in atopic dermatitis
Saini et al. New insights and treatments in atopic dermatitis
Seltmann et al. Evidence for a regulatory loop between IFN‐γ and IL‐33 in skin inflammation
Malik et al. An update on the pathophysiology of atopic dermatitis
Angkasekwinai Th9 cells in allergic disease
Chiricozzi et al. Targeting IL-4 for the treatment of atopic dermatitis
Wolk et al. The Th17 cytokine IL‐22 induces IL‐20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis
Noda et al. The translational revolution and use of biologics in patients with inflammatory skin diseases
D’Erme et al. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy
Zheng et al. Leptin enhances TH2 and ILC2 responses in allergic airway disease
Grassi‐Oliveira et al. Increased soluble tumor necrosis factor‐α receptors in patients with major depressive disorder
Su et al. Expression of NLPR3 in psoriasis is associated with enhancement of interleukin-1β and caspase-1
Kraft et al. Dupilumab in the treatment of moderate-to-severe atopic dermatitis
Brauweiler et al. Staphylococcus aureus lipoteichoic acid damages the skin barrier through an IL-1–mediated pathway
Dębińska New treatments for atopic dermatitis targeting skin barrier repair via the regulation of FLG expression
Wichmann et al. Isolation of α‐toxin‐producing Staphylococcus aureus from the skin of highly sensitized adult patients with severe atopic dermatitis
Oliva et al. The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases
Loh et al. Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis
Renert-Yuval et al. Monoclonal antibodies for the treatment of atopic dermatitis
Tubau et al. Therapeutic targeting of the IL-13 pathway in skin inflammation